...GlaxoSmithKline's immunology powerhouse, Nucala, for the treatment of hypereosinophilic syndrome (HES), a rare white blood cell disease. This latest nod gives Nucala an edge over one of its strongest competitors, AstraZeneca's Fasenra, which is also pursuing HES approval. Nucala is best known for its treatment of eosinophilic asthma, where it holds preferred status under the pharmacy benefit for 2% of covered lives, growing to 31% with utilization management restrictions.
SOURCE: MMIT Analytics, as of 9/30/20
No comments:
Post a Comment